Skip to main content
Top
Published in: Archives of Gynecology and Obstetrics 4/2006

01-07-2006 | Review

Polycystic ovary syndrome: etiology and pathogenesis

Authors: I. Matalliotakis, A. Kourtis, Ourania Koukoura, D. Panidis

Published in: Archives of Gynecology and Obstetrics | Issue 4/2006

Login to get access

Abstract

Objective: To provide a review of the pathogenesis of polycystic ovary syndrome. Design: Literature survey. Result(s): Three major pathophysiologic hypotheses have been proposed to explain the clinical findings of polycystic ovary syndrome (PCOS) related to three major laboratory findings: the LH hypothesis, the insulin hypothesis and the ovarian hypothesis. Although the presence of many small follicles with a high androgen to estrogen ratio was first thought to represent a high rate of follicular atresia in polycystic ovaries, recent studies have demonstrated that the granulosa cells are viable and able to respond to FSH stimulation with normal increases in estradiol production. Thus, a new hypothesis has arisen that FSH activity is somehow blocked at the ovarian level. Conclusion(s): PCOS is a syndrome involving defects in primary cellular control mechanisms that result in the expression of chronic anovulation and hyperandrogenism. In this syndrome, the relation between the various parameters is of particular interest. These relations constitute the cornerstone of the pathogenesis of PCOS. The fact that the pathogenesis of PCOS has not yet been clarified, despite the plethora of relative information, may be the result of a general way of thinking in the interpretation of several scientific data, and especially those that refer to biochemical phenomena. The use of the various models of the theory of chaos, that permits a concrete approach for the interpretation of data, may constitute an optional procedure for the future understanding of the association of different parameters and their disturbances in the pathogenesis of the polycystic ovary syndrome.
Literature
1.
go back to reference Stein IF, Leventhal ML (1935) Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol 29:181–188 Stein IF, Leventhal ML (1935) Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol 29:181–188
2.
go back to reference Insler V, Lunenfeld B (1991) Pathophysiology of polycystic ovarian disease: new insights. Hum Reprod 6:1025–1029PubMed Insler V, Lunenfeld B (1991) Pathophysiology of polycystic ovarian disease: new insights. Hum Reprod 6:1025–1029PubMed
3.
go back to reference Taylor AE (1998) Polycystic ovary syndrome. Endocr Metab Clin N Am 27:877–903CrossRef Taylor AE (1998) Polycystic ovary syndrome. Endocr Metab Clin N Am 27:877–903CrossRef
4.
go back to reference Franks S, Gharani N, Waterworth D, Batty S, White D, Williamson R, McCarthy M (1998) Current developments in the molecular genetics of the polycystic ovary syndrome. Trends Endocr Metab 9:51–56CrossRef Franks S, Gharani N, Waterworth D, Batty S, White D, Williamson R, McCarthy M (1998) Current developments in the molecular genetics of the polycystic ovary syndrome. Trends Endocr Metab 9:51–56CrossRef
5.
go back to reference Yen SSC, Vela P, Rankin J (1970) Inappropriate secretion of follicle stimulating hormone and luteinizing hormone in polycystic ovarian disease. J Clin Endocrinol Metab 30:435–42PubMed Yen SSC, Vela P, Rankin J (1970) Inappropriate secretion of follicle stimulating hormone and luteinizing hormone in polycystic ovarian disease. J Clin Endocrinol Metab 30:435–42PubMed
6.
go back to reference Krnjevic K (1974) Chemical nature of synaptic transmission in vertebrates. Physiol Rev 54:418–421 Krnjevic K (1974) Chemical nature of synaptic transmission in vertebrates. Physiol Rev 54:418–421
7.
go back to reference Florey E (1967) Neurotransmitters and modulators in the animal kingdom. Fed Proc 26:1164–1168PubMed Florey E (1967) Neurotransmitters and modulators in the animal kingdom. Fed Proc 26:1164–1168PubMed
8.
go back to reference Alves SE, Lopez V, McEven BS, Weiland NS (1998) Differential colocalization of estrogen receptor beta (ERbeta) with oxytocin and vasopresssin in the paraventricular and supraortic nuclei of the female rat brain: an immunocytochemical study. Proc Natl Acad Sci USA 95:3281–3286PubMedCrossRef Alves SE, Lopez V, McEven BS, Weiland NS (1998) Differential colocalization of estrogen receptor beta (ERbeta) with oxytocin and vasopresssin in the paraventricular and supraortic nuclei of the female rat brain: an immunocytochemical study. Proc Natl Acad Sci USA 95:3281–3286PubMedCrossRef
9.
go back to reference Greco B, Edwards DA, Michae RP, Clancy AN (1998) Androgen receptors and estrogen receptors are colocalized in male rat hypothalamic and limbic neurons that express Fos Immunoreactivity induced by mating. Neuroendocrinology 67:18–28PubMedCrossRef Greco B, Edwards DA, Michae RP, Clancy AN (1998) Androgen receptors and estrogen receptors are colocalized in male rat hypothalamic and limbic neurons that express Fos Immunoreactivity induced by mating. Neuroendocrinology 67:18–28PubMedCrossRef
10.
go back to reference Paganini-Hill A, Henderson VW (1994) Estrogen deficiency and risk of Alzheimer’s disease. Am J Epidemiol 140:256–261PubMed Paganini-Hill A, Henderson VW (1994) Estrogen deficiency and risk of Alzheimer’s disease. Am J Epidemiol 140:256–261PubMed
11.
go back to reference Panidis D, Matalliotakis I, Rousso D, Kourtis A, Koumantakis E (2001) The role of estrogen replacement therapy in Alzheimer’s disease. Eur J Obstet Gynecol Reprod Biol 95:86–91PubMedCrossRef Panidis D, Matalliotakis I, Rousso D, Kourtis A, Koumantakis E (2001) The role of estrogen replacement therapy in Alzheimer’s disease. Eur J Obstet Gynecol Reprod Biol 95:86–91PubMedCrossRef
12.
go back to reference Pinkerton JV, Henderson VW (2005) Estrogen and cognition, with a focus on Alzheimer’s disease. Semin Reprod Med 23:172–179PubMedCrossRef Pinkerton JV, Henderson VW (2005) Estrogen and cognition, with a focus on Alzheimer’s disease. Semin Reprod Med 23:172–179PubMedCrossRef
13.
go back to reference MacLusky NJ (2004) Estrogen and Alzheimer’s disease: the apolipoprotein connection. Endocrinology 145:3062–3064PubMedCrossRef MacLusky NJ (2004) Estrogen and Alzheimer’s disease: the apolipoprotein connection. Endocrinology 145:3062–3064PubMedCrossRef
14.
go back to reference Green PS, Bishop J, Simpkins JW (1997) 17α-Estradiol exerts neuroprotective effects on SK-N-SH cells. J Neurosci 17:511–515PubMed Green PS, Bishop J, Simpkins JW (1997) 17α-Estradiol exerts neuroprotective effects on SK-N-SH cells. J Neurosci 17:511–515PubMed
15.
go back to reference Henderson VW (1997) The epidemiology of estrogen replacement therapy and Alzheimer’s disease. Neurology 48:27–35 Henderson VW (1997) The epidemiology of estrogen replacement therapy and Alzheimer’s disease. Neurology 48:27–35
16.
go back to reference Shah RD, Anderson KL, Rapoport M, Ferreira A (2003) Estrogen-induced changes in the microtubular system correlate with a decreased susceptibility of aging neurons to beta amyloid neurotoxicity. Mol Cell Neurosci 24:503–516PubMedCrossRef Shah RD, Anderson KL, Rapoport M, Ferreira A (2003) Estrogen-induced changes in the microtubular system correlate with a decreased susceptibility of aging neurons to beta amyloid neurotoxicity. Mol Cell Neurosci 24:503–516PubMedCrossRef
17.
go back to reference Paganini-Hill A (1996) Oestrogen replacement therapy and Alzheimer’s disease. Br J Obstet Gynaecol 103(Suppl 13):80–86PubMed Paganini-Hill A (1996) Oestrogen replacement therapy and Alzheimer’s disease. Br J Obstet Gynaecol 103(Suppl 13):80–86PubMed
18.
go back to reference Paganini-Hill A (1997) Does estrogen replacement therapy protect against Alzheimer’s disease? Osteoporosis Int (Suppl) 1:512–517 Paganini-Hill A (1997) Does estrogen replacement therapy protect against Alzheimer’s disease? Osteoporosis Int (Suppl) 1:512–517
19.
go back to reference Naftolin F, Brawer JR (1978) The effect of estrogens on hypothalamic structure and function. Am J Obstet Gynecol 132:758–765PubMed Naftolin F, Brawer JR (1978) The effect of estrogens on hypothalamic structure and function. Am J Obstet Gynecol 132:758–765PubMed
20.
go back to reference Finch EC, Felicio LS, Mobbs CV, Nelson JF (1984) Ovarian and steroid influences on neuroendocrine aging process in the female rodent. Endocrinol Rev 5:467–497CrossRef Finch EC, Felicio LS, Mobbs CV, Nelson JF (1984) Ovarian and steroid influences on neuroendocrine aging process in the female rodent. Endocrinol Rev 5:467–497CrossRef
21.
go back to reference Naftolin F, Maclusky NJ, Leranth C, Sakamoto HS, Garcia-Segura LM (1988) The cellular effects of estrogens on neuroendocrine tissues. J Steroid Biochem 30:195–207PubMedCrossRef Naftolin F, Maclusky NJ, Leranth C, Sakamoto HS, Garcia-Segura LM (1988) The cellular effects of estrogens on neuroendocrine tissues. J Steroid Biochem 30:195–207PubMedCrossRef
22.
go back to reference Matsumoto A, Arai Y (1981) Neuronal plasticity in the differentiated hypothalamic arcuate nucleus of adult female rats and its enhancement by treatment with estrogen. J Comp Neurol 197:197–205PubMedCrossRef Matsumoto A, Arai Y (1981) Neuronal plasticity in the differentiated hypothalamic arcuate nucleus of adult female rats and its enhancement by treatment with estrogen. J Comp Neurol 197:197–205PubMedCrossRef
23.
go back to reference Garcia-Segura LM, Hernandez P, Olmos G, Tranque PA, Naftolin F (1988) Neuronal membrane remodeling during the oestrus cycle: a freeze fracture study in the arcuate nucleus of the rat hypothalamus. J Neurocytol 17:377–383PubMedCrossRef Garcia-Segura LM, Hernandez P, Olmos G, Tranque PA, Naftolin F (1988) Neuronal membrane remodeling during the oestrus cycle: a freeze fracture study in the arcuate nucleus of the rat hypothalamus. J Neurocytol 17:377–383PubMedCrossRef
24.
go back to reference Naftolin F, Garcia-Secura LM, Keefe C, Leranth C, Maclusky NJ, Brawer JR (1990) Estrogen effects on the synaptology and neural membranes of the rat hypothalamic arcuate nucleus. Biol Reprod 41:21–28CrossRef Naftolin F, Garcia-Secura LM, Keefe C, Leranth C, Maclusky NJ, Brawer JR (1990) Estrogen effects on the synaptology and neural membranes of the rat hypothalamic arcuate nucleus. Biol Reprod 41:21–28CrossRef
25.
go back to reference Marshall J (1998) Regulation of gonadotropin secretion in PCOS. In: Program and abstracts of the international conference on the polycystic ovary syndrome, Athens 21 Marshall J (1998) Regulation of gonadotropin secretion in PCOS. In: Program and abstracts of the international conference on the polycystic ovary syndrome, Athens 21
26.
go back to reference Spratt DI, Finkelstein JS, Butler JP et al (1987) Effects of increasing the frequency of low doses of gonadotropin-releasing hormone (GnRH) on gonadotropin secretion in GnRH-deficient men. J Clin Endocrinol Metab 64:1179–1186PubMed Spratt DI, Finkelstein JS, Butler JP et al (1987) Effects of increasing the frequency of low doses of gonadotropin-releasing hormone (GnRH) on gonadotropin secretion in GnRH-deficient men. J Clin Endocrinol Metab 64:1179–1186PubMed
27.
go back to reference Hall JE, Taylor AE, Martin KA, Rivier J, Schoenfeld DA, Crowley WF (1994) Decreased release of gonadotropin-releasing hormone during the preovulatory midcycle luteinizing hormone surge in normal women. Proc Natl Acad Sci USA 91:6894–6898PubMedCrossRef Hall JE, Taylor AE, Martin KA, Rivier J, Schoenfeld DA, Crowley WF (1994) Decreased release of gonadotropin-releasing hormone during the preovulatory midcycle luteinizing hormone surge in normal women. Proc Natl Acad Sci USA 91:6894–6898PubMedCrossRef
28.
go back to reference Hayes FJ, Taylor AE, Martin KA, Hall JE (1998) Use of a GnRH antagonist as a physiologic probe in polycystic ovary syndrome: Assessment of the neuroendocrine and androgen dynamics. J Clin Endocrinol Metab 83:2343–2349PubMedCrossRef Hayes FJ, Taylor AE, Martin KA, Hall JE (1998) Use of a GnRH antagonist as a physiologic probe in polycystic ovary syndrome: Assessment of the neuroendocrine and androgen dynamics. J Clin Endocrinol Metab 83:2343–2349PubMedCrossRef
29.
go back to reference Nestler JE (1998) Polycystic ovary syndrome: a disorder for the generalist. Fertil Steril 70:811–812PubMedCrossRef Nestler JE (1998) Polycystic ovary syndrome: a disorder for the generalist. Fertil Steril 70:811–812PubMedCrossRef
30.
go back to reference Pugeat M, Ducluzeau PH (1999) Insulin resistance, polycystic ovary syndrome and metformin. Drugs 58(Suppl 1):41–46PubMedCrossRef Pugeat M, Ducluzeau PH (1999) Insulin resistance, polycystic ovary syndrome and metformin. Drugs 58(Suppl 1):41–46PubMedCrossRef
31.
go back to reference Legro RS, Gnatuk CL, Kunselman AR, Dunaif A (2005) Changes in glucose tolerance over time in women with polycystic ovary syndrome: a controlled study. J Clin Endocrinol Metab 90(6):3236–3242PubMedCrossRef Legro RS, Gnatuk CL, Kunselman AR, Dunaif A (2005) Changes in glucose tolerance over time in women with polycystic ovary syndrome: a controlled study. J Clin Endocrinol Metab 90(6):3236–3242PubMedCrossRef
32.
go back to reference Song SH, Rhodes CJ, Veldhuis JD, Butler PC (2003) Diazoxide attenuates glucose-induced defects in first-phase insulin release and pulsatile insulin secretion in human islets. Endocrinology 144:3399–3405PubMedCrossRef Song SH, Rhodes CJ, Veldhuis JD, Butler PC (2003) Diazoxide attenuates glucose-induced defects in first-phase insulin release and pulsatile insulin secretion in human islets. Endocrinology 144:3399–3405PubMedCrossRef
33.
go back to reference Panidis D, Skiadopoulos S, Rousso D, Ioannides D, Panidou E (1995) Association of acanthosis nigricans with insulin resistance in polycystic ovary syndrome. Br J Dermatol 132:936–941PubMedCrossRef Panidis D, Skiadopoulos S, Rousso D, Ioannides D, Panidou E (1995) Association of acanthosis nigricans with insulin resistance in polycystic ovary syndrome. Br J Dermatol 132:936–941PubMedCrossRef
34.
go back to reference Panidis DK, Rousso DH, Matalliotakis IM, Kourtis AI, Vlassis GD, Koumantakis EE (1999) Hyperinsulinemia does not influence androgens/estrogens ratio in patients with polycystic ovary syndrome. Int J Fertil Womens Med 44:301–306PubMed Panidis DK, Rousso DH, Matalliotakis IM, Kourtis AI, Vlassis GD, Koumantakis EE (1999) Hyperinsulinemia does not influence androgens/estrogens ratio in patients with polycystic ovary syndrome. Int J Fertil Womens Med 44:301–306PubMed
35.
go back to reference Remsberg KE, Talbott EO, Zborowski JV, Evans RW, McHugh-Pemu K (2002) Evidence for competing effects of body mass, hyperinsulinemia, insulin resistance, and androgens on leptin levels among lean, overweight, and obese women with polycystic ovary syndrome. Fertil Steril 78:479–486PubMedCrossRef Remsberg KE, Talbott EO, Zborowski JV, Evans RW, McHugh-Pemu K (2002) Evidence for competing effects of body mass, hyperinsulinemia, insulin resistance, and androgens on leptin levels among lean, overweight, and obese women with polycystic ovary syndrome. Fertil Steril 78:479–486PubMedCrossRef
36.
go back to reference Nestler JE, Jakubowicz DJ, Evans WS, Pasquali R (1998) Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N Engl J Med 338:1876–1880PubMedCrossRef Nestler JE, Jakubowicz DJ, Evans WS, Pasquali R (1998) Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N Engl J Med 338:1876–1880PubMedCrossRef
37.
go back to reference Glueck CJ, Philips H, Cameron D, Sieve-Smith L, Wang P (2001) Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot study. Fertil Steril 75:46–52PubMedCrossRef Glueck CJ, Philips H, Cameron D, Sieve-Smith L, Wang P (2001) Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot study. Fertil Steril 75:46–52PubMedCrossRef
38.
go back to reference Vandermolen DT, Ratts VS, Evans WS, Stovall DW, Kauma SW, Nestler JE (2001) Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic syndrome who are resistent to clomiphene citrate alone. Fertil Steril 75:310–315PubMedCrossRef Vandermolen DT, Ratts VS, Evans WS, Stovall DW, Kauma SW, Nestler JE (2001) Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic syndrome who are resistent to clomiphene citrate alone. Fertil Steril 75:310–315PubMedCrossRef
39.
go back to reference Cicek MN, Bala A, Celik C, Akyurek C (2003) The comparison of clinical and hormonal parameters in PCOS patients treated with metformin and GnRH analogue. Arch Gynecol Obstet 268(2):107–112PubMed Cicek MN, Bala A, Celik C, Akyurek C (2003) The comparison of clinical and hormonal parameters in PCOS patients treated with metformin and GnRH analogue. Arch Gynecol Obstet 268(2):107–112PubMed
40.
go back to reference Poretsky L, Grigorescu F, Seibel M, Moses AC, Flier JS (1985) Distribution and characterization of insulin and insulin-like growth factor I receptors in normal human ovary. J Clin Endocrinol Metab 61:728–734PubMedCrossRef Poretsky L, Grigorescu F, Seibel M, Moses AC, Flier JS (1985) Distribution and characterization of insulin and insulin-like growth factor I receptors in normal human ovary. J Clin Endocrinol Metab 61:728–734PubMedCrossRef
41.
go back to reference Nestler JE, Jakubowicz DJ, de Vargas AF, Brik C, Quintero N, Medina F (1998) Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system. J Clin Endocrinol Metab 83:2001–2005PubMedCrossRef Nestler JE, Jakubowicz DJ, de Vargas AF, Brik C, Quintero N, Medina F (1998) Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system. J Clin Endocrinol Metab 83:2001–2005PubMedCrossRef
42.
go back to reference Moxham CP, Duronio V, Jacobs S (1989) Insulin-like growth factor I receptor beta-subunit heterogeneity: Evidence for hybrid tetramers composed of insulin-like growth factor I and insulin receptor heterodimers. J Biol Chem 264:13238–13244PubMed Moxham CP, Duronio V, Jacobs S (1989) Insulin-like growth factor I receptor beta-subunit heterogeneity: Evidence for hybrid tetramers composed of insulin-like growth factor I and insulin receptor heterodimers. J Biol Chem 264:13238–13244PubMed
43.
go back to reference Willis D, Franks S (1995) Insulin action in human granulosa cells from normal and polycystic ovaries is mediated by the insulin receptor and not the type-I insulin-like growth factor receptor. J Clin Endocrinol Metab 80:3788–3790PubMedCrossRef Willis D, Franks S (1995) Insulin action in human granulosa cells from normal and polycystic ovaries is mediated by the insulin receptor and not the type-I insulin-like growth factor receptor. J Clin Endocrinol Metab 80:3788–3790PubMedCrossRef
44.
go back to reference Schroder AK, Tauchert S, Ortmann O, Diedrich K, Weiss JM (2004) Insulin resistance in patients with polycystic ovary syndrome. Ann Med 36:426–439PubMedCrossRef Schroder AK, Tauchert S, Ortmann O, Diedrich K, Weiss JM (2004) Insulin resistance in patients with polycystic ovary syndrome. Ann Med 36:426–439PubMedCrossRef
45.
go back to reference Weiss JM, Polack S, Diedrich K, Ortmann O (2003) Effects of insulin on luteinising hormone and prolactin secretion and calcium signalling in female rat pituitary cells. Arch Gynecol Obstet 269(1):45–50PubMedCrossRef Weiss JM, Polack S, Diedrich K, Ortmann O (2003) Effects of insulin on luteinising hormone and prolactin secretion and calcium signalling in female rat pituitary cells. Arch Gynecol Obstet 269(1):45–50PubMedCrossRef
46.
go back to reference Patel K, Coffler MS, Dahan MH, Yoo RY, Lawson MA, Malcom PJ, Chang RJ (2003) Increased luteinizing hormone secretion in women with polycystic ovary syndrome is unaltered by prolonged insulin infusion. J Clin Endocrinol Metab 88(11):5456–5461PubMedCrossRef Patel K, Coffler MS, Dahan MH, Yoo RY, Lawson MA, Malcom PJ, Chang RJ (2003) Increased luteinizing hormone secretion in women with polycystic ovary syndrome is unaltered by prolonged insulin infusion. J Clin Endocrinol Metab 88(11):5456–5461PubMedCrossRef
47.
go back to reference Belli SH, Graffigna MN, Oneto A, Otero P, Schurman L, Levalle OA (2004) Effect of rosiglitazone on insulin resistance, growth factors, and reproductive disturbances in women with polycystic ovary syndrome. Fertil Steril 81:624–629PubMedCrossRef Belli SH, Graffigna MN, Oneto A, Otero P, Schurman L, Levalle OA (2004) Effect of rosiglitazone on insulin resistance, growth factors, and reproductive disturbances in women with polycystic ovary syndrome. Fertil Steril 81:624–629PubMedCrossRef
48.
go back to reference Pasquali R, Antenucci D, Casimirri F, Ventruoli S, Paradisi R, Fabbri R, Balestra V, Melchionda N, Barbara L (1989) Clinical and hormonal characteristics of obese amenorrheic hyperandrogenic women before and after weight loss. J Clin Endocrinol Metab 68:173–179PubMed Pasquali R, Antenucci D, Casimirri F, Ventruoli S, Paradisi R, Fabbri R, Balestra V, Melchionda N, Barbara L (1989) Clinical and hormonal characteristics of obese amenorrheic hyperandrogenic women before and after weight loss. J Clin Endocrinol Metab 68:173–179PubMed
49.
go back to reference Kiddy DS, Hamilton-Fairley D, Bush A, Short F, Anyaoku V, Reed MJ, Franks S (1992) Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 36:105–111CrossRef Kiddy DS, Hamilton-Fairley D, Bush A, Short F, Anyaoku V, Reed MJ, Franks S (1992) Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 36:105–111CrossRef
50.
go back to reference Nestler JE, Jakubowicz DJ (1996) Decreases in ovarian cytochrome P450c17-alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N Engl J Med 335:617–623PubMedCrossRef Nestler JE, Jakubowicz DJ (1996) Decreases in ovarian cytochrome P450c17-alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N Engl J Med 335:617–623PubMedCrossRef
51.
go back to reference Kumari AS, Haq A, Jayasundaram R, Abdel-Wareth LO, Al Haija SA, Alvares M (2005) Metformin monotherapy in lean women with polycystic ovary syndrome. Reprod Biomed Online 10:100–104PubMedCrossRef Kumari AS, Haq A, Jayasundaram R, Abdel-Wareth LO, Al Haija SA, Alvares M (2005) Metformin monotherapy in lean women with polycystic ovary syndrome. Reprod Biomed Online 10:100–104PubMedCrossRef
52.
go back to reference Morin-Papunen LC, Vauhkonen I, Koivunen RM, Ruokonen A, Martikainen HK, Tapainen JS (2000) Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study. J Clin Endocrinol Metab 85:3161–3168PubMedCrossRef Morin-Papunen LC, Vauhkonen I, Koivunen RM, Ruokonen A, Martikainen HK, Tapainen JS (2000) Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study. J Clin Endocrinol Metab 85:3161–3168PubMedCrossRef
53.
go back to reference Azziz R, Ehrmann DA, Legro RS, Fereshetian AG, O’Keefe M, Ghazzi MN (2003) PCOS/Troglitazone Study Group. Troglitazone decreases adrenal androgen levels in women with polycystic ovary syndrome. Fertil Steril 79:932–937PubMedCrossRef Azziz R, Ehrmann DA, Legro RS, Fereshetian AG, O’Keefe M, Ghazzi MN (2003) PCOS/Troglitazone Study Group. Troglitazone decreases adrenal androgen levels in women with polycystic ovary syndrome. Fertil Steril 79:932–937PubMedCrossRef
54.
go back to reference Ehrmann DA, Schneider DJ, Sobel BE, Cavaghan MK, Imperial J, Rosenfield RI, Polonsky KS (1997) Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J Clin Endocrinol Metab 82:2108–2116PubMedCrossRef Ehrmann DA, Schneider DJ, Sobel BE, Cavaghan MK, Imperial J, Rosenfield RI, Polonsky KS (1997) Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J Clin Endocrinol Metab 82:2108–2116PubMedCrossRef
55.
go back to reference Sanaka M, Iwamoto Y (2000) Troglitazone for treatment of polycystic ovary syndrome. Nippon Rinsho 58:465–470PubMed Sanaka M, Iwamoto Y (2000) Troglitazone for treatment of polycystic ovary syndrome. Nippon Rinsho 58:465–470PubMed
56.
go back to reference Gilling-Smith C, Willis DS, Beard RW, Franks S (1994) Hypersecretion of androstenedione by isolated theca cells from polycystic ovaries. J Clin Endocrinol Metab 79:1158–1165PubMedCrossRef Gilling-Smith C, Willis DS, Beard RW, Franks S (1994) Hypersecretion of androstenedione by isolated theca cells from polycystic ovaries. J Clin Endocrinol Metab 79:1158–1165PubMedCrossRef
57.
go back to reference Ibanez L, Hall JE, Potau N, Carrascosa A, Prat N, Taylor AE (1996) Ovarian 17-hydroxyprogesterone hyperresponsiveness to gonadotropin-releasing hormone (GnRH) agonist challenge in women with polycystic ovary syndrome is not mediated by luteinizing hormone hypersecretion: evidence from GnRH agonist and human chorionic gonadotropin stimulation testing. J Clin Endocrinol Metab 81:4103–4107PubMedCrossRef Ibanez L, Hall JE, Potau N, Carrascosa A, Prat N, Taylor AE (1996) Ovarian 17-hydroxyprogesterone hyperresponsiveness to gonadotropin-releasing hormone (GnRH) agonist challenge in women with polycystic ovary syndrome is not mediated by luteinizing hormone hypersecretion: evidence from GnRH agonist and human chorionic gonadotropin stimulation testing. J Clin Endocrinol Metab 81:4103–4107PubMedCrossRef
58.
go back to reference Levrant SG, Barnes RB, Rosenfield RL (1997) A pilot study of the human chorionic gonadotrophin test for ovarian hyperandrogenism. Hum Reprod 12:1416–1420PubMedCrossRef Levrant SG, Barnes RB, Rosenfield RL (1997) A pilot study of the human chorionic gonadotrophin test for ovarian hyperandrogenism. Hum Reprod 12:1416–1420PubMedCrossRef
59.
go back to reference Gilling-Smith C, Story H, Rogers V, Franks S (1997) Evidence for a primary abnormality of thecal cell steroidogenesis in the polycystic ovary syndrome. Clin Endocrinol 47:93–99CrossRef Gilling-Smith C, Story H, Rogers V, Franks S (1997) Evidence for a primary abnormality of thecal cell steroidogenesis in the polycystic ovary syndrome. Clin Endocrinol 47:93–99CrossRef
60.
go back to reference Rosenfield RL (1997) Is polycystic ovary syndrome a neuroendocrine or an ovarian disorder? Clin Endocrinol (Oxf) 47:423–424CrossRef Rosenfield RL (1997) Is polycystic ovary syndrome a neuroendocrine or an ovarian disorder? Clin Endocrinol (Oxf) 47:423–424CrossRef
61.
go back to reference Legro RS, Chiu P, Kunselman AR, Bentley CM, Dodson WC, Dunaif A (2005) Polycystic ovaries are common in women with hyperandrogenic chronic anovulation but do not predict metabolic or reproductive phenotype. J Clin Endocrinol Metab 90(5):2571–2579PubMedCrossRef Legro RS, Chiu P, Kunselman AR, Bentley CM, Dodson WC, Dunaif A (2005) Polycystic ovaries are common in women with hyperandrogenic chronic anovulation but do not predict metabolic or reproductive phenotype. J Clin Endocrinol Metab 90(5):2571–2579PubMedCrossRef
62.
go back to reference Sahin Y, Kelestimur F (1993) 17-Hydroxyprogesterone response to buserelin testing in the polycystic ovary syndrome. Clin Endocrinol (Oxf) 39:151–155CrossRef Sahin Y, Kelestimur F (1993) 17-Hydroxyprogesterone response to buserelin testing in the polycystic ovary syndrome. Clin Endocrinol (Oxf) 39:151–155CrossRef
63.
go back to reference Ehrmann DA, Rosenfield RL, Barnes RB, Brigell DF, Sheikh Z (1992) Detection of functional ovarian hyperandrogenism in women with androgen excess. N Engl J Med 327:157–162PubMedCrossRef Ehrmann DA, Rosenfield RL, Barnes RB, Brigell DF, Sheikh Z (1992) Detection of functional ovarian hyperandrogenism in women with androgen excess. N Engl J Med 327:157–162PubMedCrossRef
64.
go back to reference Fauser BC, Pache TD, Lamberts SW, Hop WC, de Jong FH, Dahl KD (1991) Serum bioactive and immunoreactive luteinizing hormone and follicle-stimulating hormone levels in women with cycle abnormalities, with or without polycystic ovarian disease. J Clin Endocrinol Metab 73:811–817PubMed Fauser BC, Pache TD, Lamberts SW, Hop WC, de Jong FH, Dahl KD (1991) Serum bioactive and immunoreactive luteinizing hormone and follicle-stimulating hormone levels in women with cycle abnormalities, with or without polycystic ovarian disease. J Clin Endocrinol Metab 73:811–817PubMed
65.
go back to reference Imse V, Holzapfel G, Hinney B, Kuhn W, Wuttke W (1992) Comparison of luteinizing hormone pulsatility in the serum of women suffering from polycystic ovarian disease using a bioassay and five different immunoassays. J Clin Endocrinol Metab 74:1053–1061PubMedCrossRef Imse V, Holzapfel G, Hinney B, Kuhn W, Wuttke W (1992) Comparison of luteinizing hormone pulsatility in the serum of women suffering from polycystic ovarian disease using a bioassay and five different immunoassays. J Clin Endocrinol Metab 74:1053–1061PubMedCrossRef
66.
go back to reference Arroyo A, Laughlin GA, Morales AJ, Yen SS (1997) Inappropriate gonadotropin secretion in polycystic ovary syndrome: influence of adiposity. J Clin Endocrinol Metab 82:3728–3733PubMedCrossRef Arroyo A, Laughlin GA, Morales AJ, Yen SS (1997) Inappropriate gonadotropin secretion in polycystic ovary syndrome: influence of adiposity. J Clin Endocrinol Metab 82:3728–3733PubMedCrossRef
67.
go back to reference Taylor AE, McCourt B, Martin KA, Anderson EJ, Adams JM, Schoenfeld D, Hall JE (1997) Determinants of abnormal gonadotropin secretion in clinically defined women with polycystic ovary syndrome. J Clin Endocrinol Metab 82:2248–2256PubMedCrossRef Taylor AE, McCourt B, Martin KA, Anderson EJ, Adams JM, Schoenfeld D, Hall JE (1997) Determinants of abnormal gonadotropin secretion in clinically defined women with polycystic ovary syndrome. J Clin Endocrinol Metab 82:2248–2256PubMedCrossRef
68.
go back to reference Rosenfield R (1999) Ovarian and adrenal function in polycystic ovarian syndrome. Endocrinol Metab Clin 28:265–293CrossRef Rosenfield R (1999) Ovarian and adrenal function in polycystic ovarian syndrome. Endocrinol Metab Clin 28:265–293CrossRef
69.
go back to reference Cara JF, Fan J, Azzarello J, Rosenfield RL (1990) Insulin-like growth factor-I enhances luteinizing hormone binding to rat ovarian theca-interstitial cells. J Clin Invest 86:560–565PubMedCrossRef Cara JF, Fan J, Azzarello J, Rosenfield RL (1990) Insulin-like growth factor-I enhances luteinizing hormone binding to rat ovarian theca-interstitial cells. J Clin Invest 86:560–565PubMedCrossRef
70.
go back to reference Rosenfield RL, Barnes RB, Ehrmann DA (1994) Studies of the nature of 17-hydroxyprogesterone hyperresonsiveness to gonadotropin-releasing hormone agonist challenge in functional ovarian hyperandrogenism. J Clin Endocrinol Metab 79:1686–1692PubMedCrossRef Rosenfield RL, Barnes RB, Ehrmann DA (1994) Studies of the nature of 17-hydroxyprogesterone hyperresonsiveness to gonadotropin-releasing hormone agonist challenge in functional ovarian hyperandrogenism. J Clin Endocrinol Metab 79:1686–1692PubMedCrossRef
71.
go back to reference Matthews CH, Borgato S, Beck-Peccoz P, Adams M, Tone Y, Gambino G, Casagrande S, Tedeschini G, Benedetti A, Chatterjee VK (1993) Primary amenorrhea and infertility due to a mutation in the beta-subunit of follicle-stimulating hormone. Nat Genet 5:83–86PubMedCrossRef Matthews CH, Borgato S, Beck-Peccoz P, Adams M, Tone Y, Gambino G, Casagrande S, Tedeschini G, Benedetti A, Chatterjee VK (1993) Primary amenorrhea and infertility due to a mutation in the beta-subunit of follicle-stimulating hormone. Nat Genet 5:83–86PubMedCrossRef
72.
go back to reference Shoham Z, Conway GS, Patel A, Jacobs HS (1992) Polycystic ovaries in patients with hypogonadotropic hypogonadism: similarity of ovarian response to gonadotropin stimulation in patients with polycystic ovarian syndrome. Fertil Steril 58:37–45PubMed Shoham Z, Conway GS, Patel A, Jacobs HS (1992) Polycystic ovaries in patients with hypogonadotropic hypogonadism: similarity of ovarian response to gonadotropin stimulation in patients with polycystic ovarian syndrome. Fertil Steril 58:37–45PubMed
73.
go back to reference Prelevic GM, Wurzburger MI, Balint-Peric L, Nesic JS (1990) Inhibitory effect of sandostatin on secretion of luteinising hormone and ovarian steroids in polycystic ovary syndrome. Lancet 336:900–903PubMedCrossRef Prelevic GM, Wurzburger MI, Balint-Peric L, Nesic JS (1990) Inhibitory effect of sandostatin on secretion of luteinising hormone and ovarian steroids in polycystic ovary syndrome. Lancet 336:900–903PubMedCrossRef
74.
go back to reference Willis DS, Watson H, Mason HD, Galea R, Brincat M, Franks S (1998) Premature response to luteinizing hormone of granulosa cells from anovulatory women with polycystic ovary syndrome: relevance to mechanism of anovulation. J Clin Endocrinol Metab 83:3984–3991PubMedCrossRef Willis DS, Watson H, Mason HD, Galea R, Brincat M, Franks S (1998) Premature response to luteinizing hormone of granulosa cells from anovulatory women with polycystic ovary syndrome: relevance to mechanism of anovulation. J Clin Endocrinol Metab 83:3984–3991PubMedCrossRef
75.
go back to reference Duleba AJ, Spaczynski RZ, Olive DL (1998) Insulin and insulin-like growth factor I stimulate the proliferation of human ovarian theca-interstitial cells. Fertil Steril 69:335–340PubMedCrossRef Duleba AJ, Spaczynski RZ, Olive DL (1998) Insulin and insulin-like growth factor I stimulate the proliferation of human ovarian theca-interstitial cells. Fertil Steril 69:335–340PubMedCrossRef
76.
go back to reference Magarelli PC, Zachow RJ, Magoffin DA (1996) Developmental and hormonal regulation of rat theca-cell differentiation factor secretion in ovarian follicles. Biol Reprod 55:416–420PubMedCrossRef Magarelli PC, Zachow RJ, Magoffin DA (1996) Developmental and hormonal regulation of rat theca-cell differentiation factor secretion in ovarian follicles. Biol Reprod 55:416–420PubMedCrossRef
77.
go back to reference Smyth CD, Miro F, Whitelaw PF, Howles CM, Hillier SG (1993) Ovarian thecal/interstitial androgen synthesis is enhanced by a follicle-stimulating hormone-stimulated paracrine mechanism. Endocrinology 133:1532–1538PubMedCrossRef Smyth CD, Miro F, Whitelaw PF, Howles CM, Hillier SG (1993) Ovarian thecal/interstitial androgen synthesis is enhanced by a follicle-stimulating hormone-stimulated paracrine mechanism. Endocrinology 133:1532–1538PubMedCrossRef
78.
go back to reference Layman LC, Peak DB, Xie J, Sohn SH, Reindollar RH, Gray MR (1997) Mutation analysis of the gonadotropin-releasing hormone receptor gene in idiopathic hypogonadotropic hypogonadism. Fertil Steril 68:1079–1085PubMedCrossRef Layman LC, Peak DB, Xie J, Sohn SH, Reindollar RH, Gray MR (1997) Mutation analysis of the gonadotropin-releasing hormone receptor gene in idiopathic hypogonadotropic hypogonadism. Fertil Steril 68:1079–1085PubMedCrossRef
79.
go back to reference Rabin D, Spitz I, Bercovici B, Bell J, Laufer A, Benveniste R, Polishuk W (1972) Isolated deficiency of follicle-stimulating hormone. Clinical and laboratory features. N Engl J Med 287:1313–1317PubMedCrossRef Rabin D, Spitz I, Bercovici B, Bell J, Laufer A, Benveniste R, Polishuk W (1972) Isolated deficiency of follicle-stimulating hormone. Clinical and laboratory features. N Engl J Med 287:1313–1317PubMedCrossRef
80.
go back to reference Magoffin DA (1989) Evidence that luteinizing hormone-stimulated differentiation of purified ovarian thecal-interstitial cells is mediated by both type I and type II adenosine 3’, 5’-monophosphate-dependent protein kinases. Endocrinology 125:1464–1473PubMed Magoffin DA (1989) Evidence that luteinizing hormone-stimulated differentiation of purified ovarian thecal-interstitial cells is mediated by both type I and type II adenosine 3’, 5’-monophosphate-dependent protein kinases. Endocrinology 125:1464–1473PubMed
81.
go back to reference Loh S, Wang JX, Matthews CD (2002) The influence of body mass index, basal FSH and age on the response to gonadotrophin stimulation in non-polycystic ovarian syndrome patients. Hum Reprod 17:1207–1211PubMedCrossRef Loh S, Wang JX, Matthews CD (2002) The influence of body mass index, basal FSH and age on the response to gonadotrophin stimulation in non-polycystic ovarian syndrome patients. Hum Reprod 17:1207–1211PubMedCrossRef
82.
go back to reference Pang SY, Softness B, Sweeney WJ III, New MI (1987) Hirsutism, polycystic ovarian disease, and ovarian 17-ketosteroid reductase deficiency. N Engl J Med 316:1295–1301PubMedCrossRef Pang SY, Softness B, Sweeney WJ III, New MI (1987) Hirsutism, polycystic ovarian disease, and ovarian 17-ketosteroid reductase deficiency. N Engl J Med 316:1295–1301PubMedCrossRef
83.
go back to reference Gjonaess H (1994) Ovarian electrocautery in the treatment of women with polycystic ovary syndrome (PCOS). Acta Obstet Gynecol Scand 73:407–412 CrossRef Gjonaess H (1994) Ovarian electrocautery in the treatment of women with polycystic ovary syndrome (PCOS). Acta Obstet Gynecol Scand 73:407–412 CrossRef
84.
go back to reference Gleick J (1998) Inner rhythms. In: Chaos (ed) Vintage books, New York, pp 273–300 Gleick J (1998) Inner rhythms. In: Chaos (ed) Vintage books, New York, pp 273–300
Metadata
Title
Polycystic ovary syndrome: etiology and pathogenesis
Authors
I. Matalliotakis
A. Kourtis
Ourania Koukoura
D. Panidis
Publication date
01-07-2006
Publisher
Springer-Verlag
Published in
Archives of Gynecology and Obstetrics / Issue 4/2006
Print ISSN: 0932-0067
Electronic ISSN: 1432-0711
DOI
https://doi.org/10.1007/s00404-006-0171-x

Other articles of this Issue 4/2006

Archives of Gynecology and Obstetrics 4/2006 Go to the issue